Seventeen alpha-hydroxylase deficiency.

Congenital adrenal hyperplasia includes rare genetic conditions affecting steroid hormone production. Prior research has shown that defects in cortisol biosynthesis can lead to hormonal imbalances and developmental abnormalities. It was already known that 17alpha-hydroxylase is essential for steroidogenesis. However, no prior work had resolved the specific clinical and genetic features of 17OHD in detail. This gap motivated further investigation into the diagnostic markers and treatment outcomes for this disorder. Patients with 17OHD often present with hypertension and sexual development issues, but the underlying mechanisms remain poorly understood. That uncertainty drove the need for case studies to clarify genetic mutations and therapeutic responses. Understanding these factors is crucial for improving early diagnosis and management strategies.

This case study aimed to document a patient with 17OHD and analyze the associated clinical and genetic features. The specific problem addressed was the identification of mutations in the CYP17 gene and their inheritance pattern. The motivation was to provide diagnostic insights for clinicians managing similar cases. The study also sought to evaluate treatment responses to glucocorticoid and sex hormone replacement. No prior work had fully described the combination of mutations observed in this patient. The researchers propose that such detailed case reports can guide clinical decision-making. This approach allows for better recognition of 17OHD in atypical presentations. The findings may help refine diagnostic criteria and treatment protocols.

The patient’s clinical presentation was assessed through physical examination and medical history. Biochemical analysis included measuring cortisol, sex steroids, and electrolyte levels. Genetic testing was performed using polymerase chain reaction amplification and sequencing of the CYP17 gene. The mutations were identified by comparing the patient’s DNA with reference sequences. The father and mother were tested separately to determine mutation inheritance. The study focused on mutations previously reported in Asian populations. The patient’s response to treatment was monitored through follow-up assessments. These methods allowed the researchers to confirm the diagnosis and track therapeutic outcomes.

The patient presented with a female phenotype and male karyotype (46,XY). Biochemical findings included elevated mineralocorticoids and low cortisol levels. Two mutations in the CYP17 gene were identified: S106P in exon 2 and a 9-bp deletion in exon 8. The S106P mutation was inherited from the father, and the deletion from the mother. Both mutations had been previously reported in Asia. The patient’s hypertension and hypokalemia improved with glucocorticoid replacement. Sex hormone replacement was initiated to induce development and prevent tall stature. Prophylactic gonadectomy was planned to reduce cancer risk. These results suggest that targeted genetic testing can confirm the diagnosis and guide treatment.

The authors propose that 17OHD should be considered in patients with hypokalemic hypertension and absent secondary sexual development. The study highlights the importance of genetic testing in confirming the diagnosis. The mutations identified in this case have been previously reported in Asian populations. The treatment response supports the use of glucocorticoid and potassium-sparing diuretics. Sex hormone replacement and prophylactic gonadectomy are recommended for long-term management. The findings suggest that early diagnosis can improve clinical outcomes. The researchers propose that awareness of this disorder among clinicians is essential. These conclusions are based on the patient’s clinical course and genetic findings.